JANE STREET GROUP, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.

Quarter-by-quarter ownership
JANE STREET GROUP, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$5,679,242
+4.9%
125,121
+29.7%
0.00%0.0%
Q2 2023$5,415,882
-10.8%
96,471
-28.1%
0.00%0.0%
Q1 2023$6,070,318
+111.5%
134,210
+90.1%
0.00%
+100.0%
Q4 2022$2,869,484
+568.9%
70,590
+974.4%
0.00%
Q3 2022$429,000
-93.7%
6,570
-94.1%
0.00%
-100.0%
Q2 2022$6,770,000
-87.4%
111,415
-87.0%
0.00%
-83.3%
Q1 2022$53,641,000
-28.3%
854,579
-13.4%
0.02%
-28.0%
Q4 2021$74,823,000
-16.5%
987,378
+23.3%
0.02%
-21.9%
Q3 2021$89,621,000
-57.2%
800,696
-38.0%
0.03%
-61.0%
Q2 2021$209,172,000
+35.6%
1,292,061
+2.0%
0.08%
+7.9%
Q1 2021$154,298,000
+14.0%
1,266,286
+43.2%
0.08%
+11.8%
Q4 2020$135,388,000
+424.1%
884,249
+186.3%
0.07%
+353.3%
Q3 2020$25,832,000
+16.2%
308,843
+2.1%
0.02%
-6.2%
Q2 2020$22,231,000
+951.6%
302,494
+506.8%
0.02%
+700.0%
Q1 2020$2,114,000
+13.5%
49,850
+63.1%
0.00%
-50.0%
Q4 2019$1,862,000
+231.9%
30,565
+156.7%
0.00%
+300.0%
Q2 2019$561,000
+150.4%
11,907
+90.2%
0.00%
Q1 2019$224,000
-80.0%
6,261
-84.1%
0.00%
-100.0%
Q4 2018$1,122,000
-71.1%
39,274
-55.2%
0.00%
-75.0%
Q3 2018$3,886,000
+194.4%
87,626
+290.3%
0.01%
+166.7%
Q2 2018$1,320,000
+49.0%
22,452
+15.9%
0.00%
+50.0%
Q1 2018$886,00019,3730.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders